title: [A case of dihydropyrimidine dehydrogenase (DPD) deficiency with severe side effects from UFT/Uzel administration].
abstract: 5-FU is among the drugs most frequently used in the treatment of gastrointestinal malignancies. Also, it has been reported to reveal severe side effects in the case of a dihydropyrimidine dehydrogenase (DPD) deficiency. A 75-year-old man showed severe nausea and vomiting after administration of UFT/Uzel as adjuvant chemotherapy. Because of severe thrombocytopenia and grade 4 neutropenia, platelet transfusion and G-CSF administration were performed. With time, the leukocyte, neutrophil and platelet count recovered to normal level. We strongly suspected a DPD deficiency from the result of urinary pyrimidine analysis.
authors.affiliation: Dept. of Surgery, Himeji Red Cross Hospital.
authors.forename: Kyohei
authors.initials: K
authors.lastname: Kai
authors.forename: Yoshikatsu
authors.initials: Y
authors.lastname: Endo
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yoshida
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Morikawa
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Nobuhisa
authors.forename: Takayuki
authors.initials: T
authors.lastname: Watanabe
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Yamada
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Doi
authors.forename: Akira
authors.initials: A
authors.lastname: Nakashima
authors.forename: Wataru
authors.initials: W
authors.lastname: Nagahiro
authors.forename: Shinji
authors.initials: S
authors.lastname: Ishizuka
authors.forename: Shizou
authors.initials: S
authors.lastname: Sato
authors.forename: Akira
authors.initials: A
authors.lastname: Nakashima
authors.forename: Akira
authors.initials: A
authors.lastname: Nabeyama
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D054067:Dihydropyrimidine Dehydrogenase Deficiency; D050744:Dihydrouracil Dehydrogenase (NAD+) / Q000172:deficiency* / Q000378:metabolism*; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000378:metabolism*; D006801:Humans; D008297:Male; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D005641:Tegafur; D014498:Uracil; D050744:Dihydrouracil Dehydrogenase (NAD+); D042943:Dihydrouracil Dehydrogenase (NADP)